1. Short title This Act may be cited as the Mitigating Emergency Drug Shortages Act . 2. Prioritize reviews of drug applications; incentives (a) Prioritized reviews and inspections Section 506C(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(g) ) is amended— (1) in the matter preceding paragraph (1), by striking the Secretary may and inserting the Secretary shall ; (2) in paragraph (1), by inserting prioritize and before expedite the review ; and (3) in paragraph (2), by inserting prioritize and before expedite an inspection . (b) Report Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall develop and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing legislative and regulatory recommendations— (1) to create market-based incentives or other appropriate mechanisms, sufficient to encourage— (A) the manufacture of drugs in shortage or at risk of shortage; (B) the domestic manufacture of finished dosage forms of such drugs; and (C) the domestic manufacture of active pharmaceutical ingredients for such drugs; and (2) to expand the Emerging Technology Program of the Food and Drug Administration to create or upgrade existing technologies to address drug shortage challenges and promote modern, reliable manufacturing strategies. 3. Additional manufacturer reporting requirements in response to drug shortages (a) Expansion To include active pharmaceutical ingredients Subsection (a) of section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) is amended— (1) in the matter preceding paragraph (1), by inserting or its active pharmaceutical ingredients after a drug ; and (2) in the flush text at the end— (A) by inserting or its active pharmaceutical ingredients before that is likely ; (B) or its active pharmaceutical ingredients after that drug